



IBEX Technologies Inc.
5485 Paré, Suite 100,
Montréal, Québec, Canada H4P 1P7
Tél : (514) 344-4004 Fax : (514) 344-8827

IBEX REPORTS SECOND QUARTER FISCAL 2011 RESULTS

MONTREAL, Quebec, March 23, 2011 – IBEX Technologies Inc. (TSX Venture: IBT), today reported its financial results for the six months ended January 31, 2011.

"As previously forecast, the second quarter did not produce a profit for IBEX, primarily due to an anticipated reduction in orders from several major customers", said Paul Baehr, President and CEO. "However, we do see signs of a strengthening in demand, as customer orders for the third and fourth quarter have picked up. We are also pleased to note the successful completion of our enzyme-lyophilization production project which will increase our capacity by over 100% and the completion of recruitment in our arthritis assay R&D expansion project".

FINANCIAL RESULTS FOR THE YEAR TO DATE

Sales for the six months ended January 31, 2011 were \$888,625 compared to \$1,517,693 for the same period in the prior year, representing a decrease of 41%. The net decrease in sales can be traced to softness in both the enzyme and arthritis-assay product lines, as well as the negative effect of a weak US dollar (approximately \$83,000).

Research and development expenses for the six months ended January 31, 2011 totaled \$140,758, as the Company re-started its efforts to improve the precision of its arthritis assays, and prepare for introduction of new assays. The Company did not incur any research and development expenditures in the same period ended January 31, 2010.

Net loss for the six months ended January 31, 2011 was \$331,218, compared to net earnings of \$496,870, for the same period in previous fiscal year.

Excluding R&D and Financial Expenses (i.e. foreign exchange, interest revenues and bank charges), Operating Costs for the six months ended January 31, 2011 decreased to \$1,051,937 from \$1,103,282, principally due to reduced compensation costs.

Cash, cash equivalents, and marketable securities decreased 34% over the six months ended January 31, 2011 to \$2,231,387 from \$3,033,556 on July 31, 2010. Working capital decreased to \$2,598,829 as at January 31, 2011 from \$3,278,875 as at July 31, 2010. The reduction in cash and in working capital is attributable to both the reduced sales, and to the now- completed investment in new production capacity for the Company's enzyme diagnostics.



FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2011

Sales for the quarter ended January 31, 2011 totaled \$375,650, a decrease of 57% as compared to \$871,037 in the same period of the prior year. The decline in sales is mainly attributable to the items mentioned above.

Excluding financial (i.e. foreign exchange etc.) and R&D expenses, Operating Expenses for the second quarter ended January 31, 2011 decreased by \$120,987 to \$454,401 due to reduced compensation costs.

The Company incurred a Net Loss of \$153,280 compared to Net Earnings of \$424,993 for the same period year ago. The decrease in Net Earnings, as mentioned above, is principally due to lower sales, an increase in R&D expenses, compounded by the weakening of the US dollar vs. the Canadian dollar (IBEX sells its goods in US dollars).

Cash, cash equivalents, and marketable securities decreased 22% during the quarter to \$2,231,287 from \$2,853,555. The Company's working capital was \$2,598,829 as at the end of the second quarter ended January 31, 2011 down from \$3,007,680 as at the end of the prior quarter ending October 31, 2010. As mentioned above, the principal reason for the decrease traces to the net loss in the second quarter, plus the costs associated with the now completed expansion in enzyme related production capacity.

Financial Summary for the six months ending

	January 31, 2011	January 31, 2010
Revenues	\$888,625	\$1,517,693
(Loss) Earning Before Interests, Tax, Depreciation & Amortization	(\$268,816)	\$560,481
Depreciation & Amortization	\$67,659	\$67,743
Net (Loss) Earnings	(\$331,218)	\$496,870
(Loss) Profit per Share	(\$0.01)	\$0.02
Cash, Cash Equivalents & Marketable Securities	\$2,231,287	\$2,904,889
Working Capital	\$2,598,828	\$3,433,285
Outstanding shares at report date (Common Shares)	24,703,244	24,703,244



LOOKING FORWARD

Fiscal 2011 looks to be a difficult year for IBEX due to softness in the US business environment. Additionally, the Canadian dollar is forecast to remain strong against the US dollar, which does not work in our favour. We therefore do not expect to have positive net earnings in Fiscal 2011, but expect to return to profitability in Fiscal 2012, as business conditions in the US improve.

Despite a difficult outlook for Fiscal 2011 we will have made two important investments in our future. IBEX has recently completed a project to add additional enzyme-related manufacturing capacity, and has also re-established a small R&D group with the object of improving our existing arthritis immuno assays, and adding to this product line. We expect to introduce new kits in calendar 2011, with financial benefits accruing in Fiscal 2012.

ABOUT IBEX

The Company manufactures and markets a series of proprietary enzymes (heparinases and chondroitinases). These enzymes are used in pharmaceutical research, quality assurance, and in the case of Heparinase I, in diagnostic devices which measure hemostasis in patients.

IBEX also manufactures and markets a series of arthritis assays which are widely used in pharmaceutical research. These assays enable the measurement of both the *synthesis* and *degradation* of cartilage components, and are powerful tools in the study of osteo- and rheumatoid arthritis.

For more information, please visit the Company's web site at www.ibex.ca.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

###

Safe Harbor Statement

All of the statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which IBEX does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. IBEX disclaims any intention or obligation to update these statements.

Contact:

Paul Baehr
President & CEO
IBEX Technologies Inc.
514-344-4004 x 143



CONSOLIDATED BALANCE SHEETS

UNAUDITED	January 31 , 2011 \$	July 31, 2010 \$
ASSETS		
Current assets		
Cash and cash equivalents	1,531,287	2,333,556
Marketable securities	300,000	300,000
Accounts receivable	309,140	422,761
Inventories	289,988	226,364
Prepaid expenses	29,965	68,236
Sub-total current assets	2,460,380	3,350,917
Long term deposit	8,650	8,650
Marketable securities	400,000	400,000
Property and equipment	1,150,206	760,384
Total assets	4,019,236	4,519,951
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities	261,552	472,042
Total liabilities	261,552	472,042
SHAREHOLDERS' EQUITY		
Capital stock	52,660,078	52,660,078
Contributed surplus	563,753	522,760
Deficit	(49,466,147)	(49,134,929)
Total shareholders' equity	3,757,684	4,047,909
Total liabilities and shareholders' equity	4,019,236	4,519,951
CONSOLIDATED STATEMENTS OF DEFICIT		
	January 31, 2011 \$	January 31, 2010 \$
Balance - Beginning of period	(49,134,929)	(49,641,291)
Net (loss) earnings for the period	(331,218)	496,870
Balance - End of period	(49,466,147)	(49,144,421)



CONSOLIDATED STATEMENTS OF EARNING AND COMPREHENSIVE INCOME

UNAUDITED

	Three months ended January 31st		Six months ended January 31st	
	2011 \$	2010 \$	2011 \$	2010 \$
Revenue	375,650	871,037	888,625	1,517,693
Operating expenses				
Research and Development expenses	(83,984)	-	(140,758)	-
Selling, general and administrative expenses and cost of goods sold	(422,066)	(540,414)	(984,278)	(1,035,539)
Amortization of property and equipment	(32,335)	(34,974)	(67,659)	(67,741)
Other interest and bank charges	(2,182)	(3,166)	(4,961)	(6,635)
Foreign exchange gain (loss)	8,242	129,673	(27,444)	84,960
Investment income	3,345	2,837	5,257	4,132
Total operating expenses	(528,980)	(446,044)	(1,219,843)	(1,020,823)
Net (loss) earnings and other comprehensive income	(153,330)	424,993	(331,218)	496,870
Net (loss) earnings and other comprehensive income per share Basic and diluted	\$ (0.01)	\$ 0.02	(\$0.01)	\$ 0.02

See accompanying notes



CONSOLIDATED CASH FLOW STATEMENTS

UNAUDITED

	Three months ended		Six months ended	
	January 31st		January 31st	
	2011	2010	2011	2010
	\$	\$	\$	\$
Cash flows provided by (used in):				
Operating activities				
Net (loss) profit for the period	(153,330)	424,993	(331,218)	496,870
Items not affecting cash -				
Amortization of property and equipment	32,285	34,974	67,659	67,741
Stock-based compensation costs	14,287	60,780	40,993	60,780
Cash flow relating to operating activities	(106,758)	520,747	(222,566)	625,391
Net changes in non-cash working capital items -				
Decrease (increase) in accounts receivable	55,837	170,123	113,622	480,511
Increase in inventories	(77,993)	(67,136)	(63,624)	(42,451)
Decrease (increase) in prepaid expenses	9,952	33,450	38,272	53,356
(Decrease) increase in accounts payable and accrued liabilities	(201,213)	(395,446)	(210,493)	(390,360)
Net changes in non-cash working capital balances relating to operations	(213,417)	(259,009)	(122,223)	101,056
Cash flow relating to operating activities	(320,175)	261,738	(344,789)	726,447
Investing activities				
Additions to property and equipment	(302,093)	(18,415)	(457,480)	(81,902)
Cash flow relating to financing activities	(302,093)	(18,415)	(457,480)	(81,902)
(Decrease) Increase in cash and cash equivalents during the quarter	(622,268)	243,323	(802,269)	644,545
Cash and cash equivalents - Beginning of period	2,153,555	2,661,567	2,333,556	2,260,345
Cash and cash equivalents - End of period	1,531,287	2,904,890	1,531,287	2,904,890

1. Interim financial information

These interim consolidated financial statements do not conform in all respects to the disclosure requirements of Canadian generally accepted accounting principles for annual financial statements and as such the consolidated interim financial statements should be read in conjunction with the annual consolidated financial statements for the years ended July 31, 2010 and 2009, which do conform to the disclosure requirements. These consolidated interim financial statements have been prepared using the same accounting policies as outlined in note 2 to the consolidated financial statements for the years ended July 31, 2010 and 2009 except as outlined in note 2 below.

The consolidated interim financial statements for the six months ended January 31, 2011 and for the six months ended January 31, 2010 are unaudited and have not been reviewed by the company's auditors. The results of operations for this period are not necessarily indicative of the trends of the operating results for the full year.

2. Significant accounting policies

Financial instruments

During the year ended July 31, 2008, the Company adopted the Canadian Institute of Chartered Accountants ("CICA") Handbook Section 1530, "Comprehensive Income"; Section 3251, "Equity"; Section 3855, "Financial Instruments – Recognition and Measurement"; Section 3862, "Financial Instruments – Disclosures"; Section 3863, "Financial Instruments – Presentation"; and Section 3865, "Hedges". These standards provide accounting guidelines for the recognition, measurement, disclosure and presentation of financial assets, financial liabilities and non-financial derivatives, as well as the introduction of a new statement of comprehensive income. Section 3865 did not have an impact on the Company as it does not use hedge accounting. The Company elected to early adopt Sections 3862 and 3863, as permitted by the standards.

The Company's adoption of these new financial instrument standards resulted in changes in the accounting for financial instruments, as well as the recognition of certain transitional adjustments that have been recorded in opening deficit as described below. The principal changes in the accounting for financial instruments due to the adoption of these accounting standards are as follows:

a) **Comprehensive income (loss)**

Comprehensive income (loss) is defined as the change in equity from transactions and other events and circumstances from sources other than shareholders, and is composed of the Company's net earnings (loss) and other comprehensive income (loss). Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are recognized in comprehensive income (loss) but excluded from net earnings (loss). The Company does not have any components that qualify as other comprehensive income (loss).

IBEX Technologies Inc.
Notes to Consolidated Financial Statements
For the six months ended January 31, 2011 and 2010 (unaudited)

b) Financial assets and financial liabilities

Financial assets and financial liabilities, including derivatives, are recognized on the consolidated balance sheet when the Company becomes a party to the contractual provisions of the financial instrument or non-financial derivative contract. Financial instruments are initially recognized at fair value and are classified into one of five categories: held for trading, available for sale, held to maturity, loans and receivables, or other financial liabilities. They are subsequently accounted for based on their classification as described below. The classification depends on the purpose for which the financial instruments were acquired and their characteristics. Except in very limited circumstances, the classification is not changed subsequent to initial recognition. Transaction costs are expensed as incurred.

Held for trading

Financial instruments classified as held for trading are carried at fair value at each balance sheet date with the changes in fair value recorded in net earnings (loss) in the period in which the changes arise.

Available for sale

Financial instruments classified as available for sale are carried at fair value at each balance sheet date with the changes in fair value recorded in other comprehensive income (loss) in the period in which the changes arise. Securities that are classified as available for sale and do not have a readily available market value are recorded at cost. Available-for-sale securities are adjusted to fair value through earnings (loss) whenever it is necessary to reflect other than temporary impairment. Upon derecognition, all cumulative gains or losses are then recognized in net earnings (loss).

Held to maturity, loans and receivables, and other financial liabilities

Financial instruments classified as held to maturity, loans and receivables, and other financial liabilities are carried at amortized cost using the effective interest method, and interest income or expense is included in net earnings (loss) over the expected life of the instrument.

Management has selected the following classifications and bases of accounting for the Company's financial instruments:

Asset/Liability	Classification	Basis of accounting
Cash and cash equivalents	Held for trading	Fair value
Marketable securities	Held to maturity	Amortized cost
Accounts receivable	Loans and receivable	Amortized cost
Accounts payable and accrued liabilities	Other financial liabilities	Amortized cost

c) Embedded derivatives

All derivative instruments are recorded in the consolidated balance sheet at fair value at each balance sheet date. Derivatives may be embedded in other financial instruments (the “host instrument”). Prior to the adoption of the new standards, such embedded derivatives were not accounted for separately from the host instrument. Under the new standards, embedded derivatives are treated as separate derivatives if their economic characteristics and risks are not clearly and closely related to those of the host instrument, the terms of the embedded derivative are the same as those of a stand-alone derivative, and the combined contract is not held for trading or designated at fair value. These embedded derivatives are measured at fair value at each balance sheet date with subsequent changes recognized in net earnings (loss) in the period in which the changes arise. The Company selected August 1, 2002 as its transition date for embedded derivatives, which is the latest date allowed by the accounting standard.

The Company enters into certain contracts for the sale of non-financial items that are denominated in currencies other than the Canadian dollar, the Company’s functional currency. In cases where the foreign exchange component is not leveraged, does not contain an option feature and the contract is either denominated in the functional currency of the counterparty, the non-financial item is routinely denominated in the currency of the contract or the currency of the contract is commonly used in the economic environment in which the transaction takes place, the embedded derivative is considered to be closely related and is not accounted for separately. The fair value of financial instruments is determined using recognized valuation models using observable market-based inputs.

Embedded foreign currency derivatives gave rise to a transitional adjustment for the cumulative impact of adopting these new standards for prior years, which was recognized as an adjustment directly to opening deficit of fiscal 2008. No other transitional adjustments were recorded as a result of the adoption of the new standards. The impact of the adoption was a one-time increase of \$4,711 to deficit and accounts payable and accrued liabilities.

During the six months ended January 31, 2011, no impact of the change in the fair value of the derivatives related to sales contracts was recorded in foreign exchange loss (2010: loss of \$107,618).

Capital disclosures

During the year ended July 31, 2008, the Company early adopted CICA Handbook Section 1535, “Capital Disclosures”, as permitted by the standard. The standard requires the disclosure of both qualitative and quantitative information that enables the users of the financial statements to evaluate the Company’s objectives, policies and processes for managing capital.

The adoption of this Section did not have an impact on the Company’s financial position, earnings or cash flows; however, it did result in expanded disclosure.

IBEX Technologies Inc.
Notes to Consolidated Financial Statements
For the six months ended January 31, 2011 and 2010 (unaudited)

Inventories

On August 1st, 2008, the Company adopted CICA Handbook section 3031 “Inventories”, which provides guidance on the determination of costs and their subsequent recognition as an expense, including the allocation of fixed and variable overheads, narrows the permitted costs formulas, and expands the disclosure requirements to increase transparency.

Inventories are composed of work in process and finished goods, which are valued at the lower of cost or net realizable value determined on a first-in, first-out basis. Inventory cost includes materials, direct labor and attributable overhead. During the six months ended January 31, 2011 the Company recognized an expense of \$455,635 in cost of products sold (January 31, 2010: \$463,849).

	January 31, 2011	July 31, 2010
	\$	\$
Inventories		
Assay kits	43,613	14,419
Enzymes	225,453	197,130
Work in process – enzymes	20,922	14,815
Total inventory	289,988	226,364

Goodwill and Intangible Assets

Section 3064 replaces the existing Section 3062, “Goodwill and Other Intangible Assets”, and Section 3450, “Research and Development Costs”. The standard provides guidance on the recognition, measurement and disclosures of goodwill and intangible assets. Management does not expect this Section to have a significant impact on IBEX’s financial position, earnings or cash flows.

3. Marketable securities

(a) Marketable securities include the following:

	January 31, 2011	July 31 2010
	\$	\$
Debt Securities – at cost [which approximates market value (note 2(b))]	700,000	700,000
	700,000	700,000

IBEX Technologies Inc.
Notes to Consolidated Financial Statements
For the six months ended January 31, 2011 and 2010 (unaudited)

(b) The marketable securities as at January 31, 2011 consist of GICs held at highly rated institutions which mature on April 6, 2011 in the amount of \$300,000, and March 8, 2012 in the amount of \$400,000, and have annualized yields of 1.35% and 1.95% respectively.

4. Capital stock and contributed surplus

As at January 31, 2011, the company's authorized capital stock is as follows:

(a) Unlimited as to number

- Cumulative, redeemable First preferred shares, issuable in series. The first series consisted of 150,000 shares, convertible into common shares at a rate of 188.68 voting common shares for each preferred share.
- Cumulative, redeemable convertible Second preferred shares, issuable in series.
- Third preferred shares, issuable in series.
- Common shares.

(b) Issued

Book value	January 31, 2011 \$	July 31 2010 \$
24,703,244 Common shares (2010: 24,703,244)	52,660,078	52,660,078

(c) Stock Options

As at January 31, 2011, the weighted average fair value of the previous options granted at an exercise price at or above market price is \$29,500. No options were granted during the six months ended January 31, 2011.

For the six-month period ended January 31, 2011, there was a charge to general and administrative expenses of \$40,993 and a corresponding increase to contributed surplus for stock based compensation amortization.

Under the existing IBEX Technologies Inc. ("IBEX") stock option plan, common shares may be issued to full-time employees of the company, directors and consultants, the terms and conditions of grants thereunder being contingent upon market values, the discretion of the Board of Directors and regulatory requirements. The number of common shares reserved for issuance under this stock option plan is currently 1,592,992. The maximum term permissible under the plan is 10 years which is determined at the date of grant as well as the vesting privileges.

IBEX Technologies Inc.
Notes to Consolidated Financial Statements
For the six months ended January 31, 2011 and 2010 (unaudited)

The following table summarizes the IBEX stock option plan:

	January 31, 2011		July 31 2010	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Beginning balance – July 31	1,478,385	\$ 0.26	769,385	\$ 0.26
Granted	-	-	720,000	0.23
Expired	(42,885)	0.49	(11,000)	0.52
Cancelled	-	-	-	-
Ending balance	<u>1,435,500</u>		<u>1,478,385</u>	

The following table summarizes the IBEX stock options outstanding as at January 31, 2011:

	Options outstanding			Options currently exercisable	
	Issued stock options	Weighted average remaining contractual life (years)	Weighted average exercise price	Vested stock options	Weighted average exercise price
Range of exercise prices					
\$			\$		\$
0.06	25,000	6.87	0.06	25,000	0.06
0.10	280,000	7.15	0.10	280,000	0.10
0.18-0.24	961,500	7.55	0.22	961,500	0.22
0.33-0.45	38,500	3.98	0.36	38,500	0.36
0.50-0.70	130,500	1.71	0.59	130,500	0.59
	<u>1,435,500</u>			<u>1,435,500</u>	

5. Profit (loss) per share

Loss per share is calculated using the weighted average number of shares outstanding of 24,703,244 (2010: 24,703,244). Securities which dilute profit per share are employee options.

There were no adjustments to the weighted average number of shares outstanding for purposes of calculating the diluted loss per share for the period ended of January 31, 2011 because to do so would be anti-dilutive.